Joseph A Shrader

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1520560/publications.pdf

Version: 2024-02-01

471509 377865 1,397 36 17 34 citations h-index g-index papers 36 36 36 1340 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Preliminary validation of muscle ultrasound in juvenile dermatomyositis (JDM). Rheumatology, 2022, 61, SI48-SI55.	1.9	6
2	Skeletal Muscle Magnetic Resonance Biomarkers in GNE Myopathy. Neurology, 2021, 96, e798-e808.	1.1	18
3	Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study. Genetics in Medicine, 2021, 23, 2067-2075.	2.4	23
4	Dynamic Balance in Spinal and Bulbar Muscular Atrophy: Relationship between Strength and Performance of Forward Lunge, Step Up and Over, and Step Quick Turn. Rehabilitation Research and Practice, 2021, 2021, 1-8.	0.6	0
5	Measuring the Motor Aspect of Cancer-Related Fatigue using a Handheld Dynamometer. Journal of Visualized Experiments, 2020, , .	0.3	2
6	Exercise intervention leads to functional improvement in a patient with spinal and bulbar muscular atrophy. Journal of Rehabilitation Medicine Clinical Communications, 2020, 3, jrmcc10041.	0.6	1
7	Cognitive and motor aspects of cancerâ€related fatigue. Cancer Medicine, 2019, 8, 5840-5849.	2.8	20
8	Patient reported outcomes in GNE myopathy: incorporating a valid assessment of physical function in a rare disease. Disability and Rehabilitation, 2018, 40, 1206-1213.	1.8	7
9	A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Seminars in Arthritis and Rheumatism, 2018, 47, 858-864.	3.4	49
10	Identification of an <i>Alu</i> elementâ€mediated deletion in the promoter region of <i><scp>GNE</scp> </i> Molecular Genetics & mp; Genomic Medicine, 2017, 5, 410-417.	1.2	15
11	Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. Rheumatology, 2016, 55, kev344.	1.9	41
12	Sexual Reassignment Fails to Prevent Kennedy's Disease. Journal of Neuromuscular Diseases, 2016, 3, 121-125.	2.6	9
13	A randomized controlled trial of exercise in spinal and bulbar muscular atrophy. Annals of Clinical and Translational Neurology, 2015, 2, 739-747.	3.7	30
14	Lower Extremity Peak Force and Gait Kinematics in Individuals With Inclusion Body Myositis. Arthritis Care and Research, 2015, 67, 94-101.	3.4	4
15	Corrigenda. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2800-2800.	3.6	217
16	Reliability of the Adult Myopathy Assessment Tool in Individuals With Myositis. Arthritis Care and Research, 2015, 67, 563-570.	3.4	9
17	Validity of the single limb heel raise test to predict lower extremity disablement in patients with sporadic inclusion body myositis. Disability and Rehabilitation, 2014, 36, 2270-2277.	1.8	5
18	Early onset and novel features in a spinal and bulbar muscular atrophy patient with a 68 CAG repeat. Neuromuscular Disorders, 2014, 24, 978-981.	0.6	37

#	Article	IF	CITATIONS
19	Atypical presentation of GNE myopathy with asymmetric hand weakness. Neuromuscular Disorders, 2014, 24, 1063-1067.	0.6	21
20	Assessing Function and Endurance in Adults with Spinal and Bulbar Muscular Atrophy: Validity of the Adult Myopathy Assessment Tool. Rehabilitation Research and Practice, 2014, 2014, 1-16.	0.6	28
21	Are Repeated Single-Limb Heel Raises and Manual Muscle Testing Associated With Peak Plantar-Flexor Force in People With Inclusion Body Myositis?. Physical Therapy, 2014, 94, 543-552.	2.4	20
22	Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurology, The, 2011, 10, 140-147.	10.2	138
23	Posttransplant Distal Limb Syndrome. Journal of Orthopaedic and Sports Physical Therapy, 2011, 41, 458-458.	3.5	0
24	Reply: Comment on alemtuzumab and inclusion body myositis. Brain, 2010, 133, e136-e136.	7.6	1
25	Patellofemoral Knee Pain in an Adult With Radiographic Osteoarthritis and Human Immunodeficiency Virus Infection. Journal of Orthopaedic and Sports Physical Therapy, 2009, 39, 612-617.	3.5	1
26	Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain, 2009, 132, 1536-1544.	7.6	182
27	Clinical features of spinal and bulbar muscular atrophy. Brain, 2009, 132, 3242-3251.	7.6	223
28	Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study. BMC Neurology, 2007, 7, 3.	1.8	49
29	Navicular Drop Measurement in People With Rheumatoid Arthritis: Interrater and Intrarater Reliability. Physical Therapy, 2005, 85, 656-664.	2.4	49
30	Navicular drop measurement in people with rheumatoid arthritis: interrater and intrarater reliability. Physical Therapy, 2005, 85, 656-64.	2.4	15
31	Physiotherapy management of patients with HIV-associated Kaposi's sarcoma. Physiotherapy Research International, 2004, 9, 174-181.	1.5	7
32	Nonoperative Management of Functional Hallux Limitus in a Patient With Rheumatoid Arthritis. Physical Therapy, 2003, 83, 831-843.	2.4	36
33	Nonoperative management of functional hallux limitus in a patient with rheumatoid arthritis. Physical Therapy, 2003, 83, 831-43.	2.4	8
34	Nonsurgical Management of the Foot and Ankle Affected by Rheumatoid Arthritis. Journal of Orthopaedic and Sports Physical Therapy, 1999, 29, 703-717.	3.5	16
35	Phonophoresis versus ultrasound in the treatment of common musculoskeletal conditions. Medicine and Science in Sports and Exercise, 1998, 30, 1349-1355.	0.4	100
36	Postsurgical Hindfoot Deformity of a Patient With Rheumatoid Arthritis Treated With Custom-made Foot Orthoses and Shoe Modifications. Physical Therapy, 1997, 77, 296-305.	2.4	10